Joyce O’Shaughnessy

22.3k total citations · 9 hit papers
347 papers, 14.0k citations indexed

About

Joyce O’Shaughnessy is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Joyce O’Shaughnessy has authored 347 papers receiving a total of 14.0k indexed citations (citations by other indexed papers that have themselves been cited), including 276 papers in Oncology, 147 papers in Pulmonary and Respiratory Medicine and 129 papers in Cancer Research. Recurrent topics in Joyce O’Shaughnessy's work include Cancer Treatment and Pharmacology (159 papers), HER2/EGFR in Cancer Research (130 papers) and Advanced Breast Cancer Therapies (116 papers). Joyce O’Shaughnessy is often cited by papers focused on Cancer Treatment and Pharmacology (159 papers), HER2/EGFR in Cancer Research (130 papers) and Advanced Breast Cancer Therapies (116 papers). Joyce O’Shaughnessy collaborates with scholars based in United States, United Kingdom and Spain. Joyce O’Shaughnessy's co-authors include Svetislava J. Vukelja, Hope S. Rugo, Stephen E. Jones, Javier Cortés, Joanne L. Blum, Chris Twelves, José Baselga, George W. Sledge, Frankie A. Holmes and Michael A. Savin and has published in prestigious journals such as The Lancet, JAMA and Journal of Clinical Oncology.

In The Last Decade

Joyce O’Shaughnessy

323 papers receiving 13.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results

2002 855 citations Joyce O’Shaughnessy, Vladimir Moiseyenko et al. Journal of Clinical Oncology profile →
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

2011 807 citations Javier Cortés, Joyce O’Shaughnessy et al. profile →
Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer

2010 701 citations Hope S. Rugo, Joyce O’Shaughnessy et al. Journal of Clinical Oncology profile →
Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

2010 568 citations Hope S. Rugo, Joyce O’Shaughnessy et al. Journal of Clinical Oncology profile →
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

2018 516 citations Sibylle Loibl, Joyce O’Shaughnessy et al. profile →
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development

2005 499 citations Joyce O’Shaughnessy et al. Clinical Cancer Research profile →
Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing

2012 474 citations Joyce O’Shaughnessy et al. profile →
Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer

2018 348 citations Denise A. Yardley, Lee S. Schwartzberg et al. Journal of Clinical Oncology profile →
Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06).

2024 52 citations Giuseppe Curigliano, Xichun Hu et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Joyce O’Shaughnessy

Since Specialization

Citations

This map shows the geographic impact of Joyce O’Shaughnessy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joyce O’Shaughnessy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joyce O’Shaughnessy more than expected).

Fields of papers citing papers by Joyce O’Shaughnessy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joyce O’Shaughnessy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joyce O’Shaughnessy. The network helps show where Joyce O’Shaughnessy may publish in the future.

Co-authorship network of co-authors of Joyce O’Shaughnessy

This figure shows the co-authorship network connecting the top 25 collaborators of Joyce O’Shaughnessy. A scholar is included among the top collaborators of Joyce O’Shaughnessy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joyce O’Shaughnessy. Joyce O’Shaughnessy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	436TiP DYNASTY-Breast02: A phase III trial of BNT323/DB-1303 vs investigator's choice chemotherapy in HER2-low, hormone receptor positive, metastatic breast cancer 2024 ·Annals of Oncology ·Joyce O’Shaughnessy, (unknown), P. Schmid, (unknown), Zhimin Shao, Luís Augusto Teixeira, Mehmet Alı Nahıt Şendur, Dhanusha Sabanathan, S-B. Kim, (unknown), Michael J. Wenger, Jang‐Hern Lee, (unknown), Yang Qiu, Simin Liu, Hong Fang, (unknown), Zhou Zhu, E.P. Hamilton	1
2	Abstract PO4-27-06: Design of Active Phase 3 ENABLAR-2 Study Evaluating Enobosarm +/- Abemaciclib in Patients with AR+ER+HER2- 2nd-Line Metastatic Breast Cancer Following Tumor Progression on an Estrogen Blocking Agent Plus Palbociclib or Ribociclib 2024 ·Cancer Research ·Kristine Rinn, Hannah M. Linden, Lee S. Schwartzberg, (unknown), Domingo Rodrı́guez, Itay Shalev, Mitchell S. Steiner, Adam Brufsky, Joyce O’Shaughnessy	1
3	Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). breakdown → 2024 ·Journal of Clinical Oncology ·Giuseppe Curigliano, Xichun Hu, Rebecca Dent, Kan Yonemori, Carlos H. Barrios, Joyce O’Shaughnessy, Hans Wildiers, Qingyuan Zhang, Seock‐Ah Im, Cristina Saura, Laura Biganzoli, Joohyuk Sohn, Christelle Lévy, William Jacot, (unknown), Jun Ke, Gargi Patel, Aditya Bardia	52
4	Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study 2024 ·npj Breast Cancer ·Matthew P. Goetz, İrfan Çiçin, Laura Testa, Sara M. Tolaney, Jens Huober, Valentina Guarneri, Stephen Johnston, Miguel Martín, Priya Rastogi, Nadia Harbeck, Ashwin Shahir, Ran Wei, Valérie André, Hope S. Rugo, Joyce O’Shaughnessy	12
5	Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States 2023 ·Advances in Therapy ·Min Huang, Peter A. Fasching, Amin Haiderali, (unknown), (unknown), Wilbur Pan, Zheng‐Yi Zhou, (unknown), (unknown), Celine Le Bailly De Tilleghem, (unknown), Joyce O’Shaughnessy	14
6	196P Efficacy and safety of first-line (1L) ribociclib (RIB) + letrozole (LET) in patients (pts) with de novo metastatic disease and late recurrence from (neo)adjuvant therapy (tx) in MONALEESA (ML)-2 2023 ·ESMO Open ·Joyce O’Shaughnessy, (unknown), Stephen Chia, Claudine Isaacs, Michelino De Laurentiis, Sherko Küemmel, Komal Jhaveri, Wolfgang Janni, Hope S. Rugo, Agnes Lteif, (unknown), Howard Hu, Patrick Neven	0
7	LBA18 Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study 2023 ·Annals of Oncology ·Peter Schmid, Javier Cortés, Rebecca Dent, Lajos Pusztai, Heather L. McArthur, Sherko Kümmel, Carsten Denkert, Y.H. Park, Rina Hui, (unknown), (unknown), Theodoros Foukakis, (unknown), (unknown), S-A. Im, Fátima Cardoso, Yu Ding, (unknown), Konstantinos Tryfonidis, Joyce O’Shaughnessy	20
8	LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer 2023 ·Annals of Oncology ·Fátima Cardoso, Heather L. McArthur, Peter Schmid, Javier Cortés, Nadia Harbeck, Melinda L. Telli, David W. Cescon, Joyce O’Shaughnessy, Peter A. Fasching, Zhi-Min Shao, Delphine Loirat, Y.H. Park, (unknown), (unknown), Hiroyuki Yasojima, Yu Ding, (unknown), Vassiliki Karantza, Konstantinos Tryfonidis, Aditya Bardia	67
9	Effects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients 2022 ·European Journal of Cancer ·Marion van Mackelenbergh, Fenja Seither, Volker Möbus, Joyce O’Shaughnessy, Miguel Martín, Heikki Joensuu, Michael Untch, Ulrike Nitz, Guenther G. Steger, J. Miralles, Carlos H. Barrios, Masakazu Toi, Harry D. Bear, Hyman B. Muss, Toralf Reimer, Valentina Nekljudova, Sibylle Loibl	9
10	Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups 2021 ·npj Breast Cancer ·Stephen Johnston, Joyce O’Shaughnessy, Miguel Martín, Jens Huober, Masakazu Toi, Joohyuk Sohn, Valérie André, Holly Martin, Molly Catherine Hardebeck, Matthew P. Goetz	36
11	Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis 2020 ·Cancer Research ·Min Huang, Joyce O’Shaughnessy, Jing Zhao, Amin Haiderali, Javier Cortés, Scott D. Ramsey, Andrew Briggs, (unknown), Vassiliki Karantza, Gursel Aktan, Cynthia Z. Qi, Chenyang Gu, Jipan Xie, (unknown), John S. Cook, Michael Untch, Peter Schmid, Peter A. Fasching	89
12	Real-world Evidence of Diagnostic Testing and Treatment Patterns in US Patients With Breast Cancer With Implications for Treatment Biomarkers From RNA Sequencing Data 2020 ·Clinical Breast Cancer ·(unknown), Caroline G. Epstein, Alexandria M. Bobe, Joshua S. K. Bell, Martin C. Stumpe, (unknown), Ameen A. Salahudeen, (unknown), (unknown), (unknown), (unknown), Catherine Igartua, Robert Huether, Ashraf Hafez, Nike Beaubier, Michael D. Axelson, Mark D. Pegram, Sarah Sammons, Joyce O’Shaughnessy, Gary A. Palmer	10
13	Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs 2019 ·Clinical Cancer Research ·Melody Cobleigh, Denise A. Yardley, Adam Brufsky, Hope S. Rugo, Sandra M. Swain, Peter A. Kaufman, Debu Tripathy, Sara A. Hurvitz, Joyce O’Shaughnessy, Ginny Mason, Vincent Antao, Haocheng Li, Laura Chu, Mohammad Jahanzeb	23
14	Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol 2018 ·Clinical Cancer Research ·Hope S. Rugo, Javier Cortés, Ahmad Awada, Joyce O’Shaughnessy, Chris Twelves, Seock‐Ah Im, Alison L. Hannah, Lin Lü, Sherwin K. B. Sy, (unknown), Deborah A. Zajchowski, Darren W. Davis, Mary Tagliaferri, Ute Hoch, Edith A. Perez	17
15	A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted Therapeutics 2018 ·Molecular Cancer Therapeutics ·Jelmar Quist, Hasan Mirza, Maggie C.U. Cheang, Melinda L. Telli, Joyce O’Shaughnessy, Christopher J. Lord, Andrew Tutt, Anita Grigoriadis	20
16	Everolimus-based combination therapies for HR+, HER2− metastatic breast cancer 2018 ·Cancer Treatment Reviews ·Joyce O’Shaughnessy, J. Thaddeus Beck, Melanie Royce	43
17	Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples 2014 ·Breast Cancer Research and Treatment ·Timothy R. Wilson, Yuanyuan Xiao, Jill M. Spoerke, Jane Fridlyand, Hartmut Koeppen, (unknown), Ling Huw, (unknown), (unknown), Erica Schleifman, Rupal Desai, Ling Fu, Teiko Sumiyoshi, Joyce O’Shaughnessy, Garret M. Hampton, Mark R. Lackner	21
18	Tamoxifen Downregulates Ets Oncogene Family Members ETV4 and ETV5 in Benign Breast Tissue: Implications for Durable Risk Reduction 2011 ·Cancer Prevention Research ·(unknown), Dawei Bu, (unknown), Venetia Sarode, Raheela Ashfaq, Kelly K. Hunt, Weiya Xia, Joyce O’Shaughnessy, Michael D. Grant, Banu Arun, William C. Dooley, Alexander Miller, David A. Flockhart, Cheryl Lewis	13
19	Dose-Adjusting Capecitabine Minimizes Adverse Effects While Maintaining Efficacy: A Retrospective Review of Capecitabine for Metastatic Breast Cancer 2011 ·Clinical Breast Cancer ·Robert Leonard, Bryan T. Hennessy, Joanne L. Blum, Joyce O’Shaughnessy	37
20	Xeloda (capecitabine) plus docetaxel combination therapy in locally advanced/metastatic breast cancer: Latest results 2001 ·Breast Cancer Research and Treatment ·S. Vukelja, Vladimir Moiseyenko, Robert Leonard, Pierfranco Conté, A. Garin, J. McKendrick, K. Possinger, F Turpin, Ted Vandenberg, Joyce O’Shaughnessy	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact